Please assess the completion status of the following clinical trial:

Trial Title: Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of B-cell chronic lymphocytic leukemia (CLL) meeting the following criteria at any time during the course of disease (e.g., at initial diagnosis or relapse):~  * Absolute lymphocytosis \> 5,000/mm\^3~ * Lymphocytes must appear mature with \< 55% prolymphocytes~ * More than 30% of all nucleated cells are lymphoid on bone marrow aspirate smear~ * Lymphoid infiltrates compatible with bone marrow involvement by CLL on core bone marrow biopsy~ * Predominant B-cell monoclonal population of cells share the B-cell marker (CD19) with the CD5 antigen in the absence of other pan-T-cell markers by lymphocyte immunophenotyping~* High-risk disease OR intermediate-risk disease~  * Patients in the intermediate-risk group must have evidence of active disease as demonstrated by at least 1 of the following criteria:~    * Massive or progressive splenomegaly and/or adenopathy~   * Weight loss \> 10% within the past 6 months~   * Common toxicity grade 2-4 fatigue~   * Fevers \> 100.5°F OR night sweats for more than 2 weeks without evidence of infection~   * Progressive lymphocytosis with an increase of \> 50% over a 2-month period or an anticipated doubling time of \< 6 months~* Failed at least 1 prior fludarabine regimen, as defined by 1 of the following criteria:~  * Refractory or intolerant to fludarabine~ * Relapsed within 6 months after completion of fludarabine~* No CNS leukemia~* No mantle cell lymphoma in leukemic phase~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* More than 2 months~Hematopoietic~* Absolute neutrophil count ≥ 1,000/mm\^3~* Platelet count ≥ 50,000/mm\^3~* Hemoglobin ≥ 8 g/dL (transfusion allowed)~Hepatic~* Albumin ≥ 3 g/dL~* AST and ALT ≤ 2.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* No hepatitis B or C infection~Renal~* Creatinine ≤ 1.5 mg/dL OR~* Creatinine clearance ≥ 40 mL/min~Cardiovascular~* LVEF ≥ 40%~Other~* No uncontrolled infection~* No other concurrent serious illness~* No HIV infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use two effective methods of contraception (one must be non-hormonal) during and for at least 1 month after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Prior denileukin diftitox allowed~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* No concurrent corticosteroids as anti-emetics~Radiotherapy~* No concurrent radiotherapy~Surgery~* Not specified~Other~* At least 28 days since prior anticancer therapy and recovered~* No other concurrent antineoplastic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete